Protocol Ledger

NCT03657095 · Phase III · TERMINATED

A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension

Interventional Phase III clinical trial protocol NCT03657095 sponsored by Lung Biotechnology PBC in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-12-10 Enrollment: 112 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03657095
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)112 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03657095
Protocol FieldVerified Registry Value
NCT IdentifierNCT03657095
Consolidated Lead SponsorLung Biotechnology PBC
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment112 participants (ACTUAL)
Registered Start Date2018-12-10
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI